A modelling study of respiratory syncytial virus (RSV) prevention strategies in Argentina found that either a long-acting monoclonal antibody (mAb) or maternal RSV vaccine are worth considering when priced at <US$50 per dose. Researchers used a static proportionate outcomes model to calculate the costs and consequences of using RSV mAb or maternal RSV vaccine over a ten-year period (2025–2034) in Argentina, assuming both year-round and seasonal administration. The primary outcome was the discounted cost per disability-adjusted life year (DALY) averted from a societal perspective.
Either strategy was found to potentially prevent >25% of RSV deaths aged <5 years and ∼30% aged <6 months (the age group where most intervention impact occurs). With a dose price of $US 50, both products have a 100% probability of being cost-effective compared to no intervention. Similar health impact could be achieved by a six-month seasonal strategy, which could improve cost-effectiveness by around 45% (assuming the dose price is unchanged).
Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.